Member Info for Soupdragon78

Also interesting that in the last interview Riddell said that once they had this info they would be starting business development activity.

With regards to Allenby, it would be good for them to give an update, although I think it would be more likely that they will be compiling their next report to tie in with interims that are due in less than a months time.
That will contain the revenues from NXP001 (no matter how big or small) and also the NXP004 update as well as the successful NXP002 package.

The durability isn't a deal breaker. We know the product can be used with a nebuliser which makes it perfect for lung treatments. We know its more effective than the market leaders.

This really now needs to be on the big boys (and girls) radars.

The release of this as an RNS makes sense. Riddell stated they would be getting them.

In the interview Riddell stated... 'As we get the results in the next few weeks on these suite of studies and we expect them to be positive, we don't know how positive yet...'

What’s AIM for to do with NFX?

Great news! This is exactly what Anne was brought in to do and couldn’t have been done without her.

“We’re focused on the quality, the right patient selection is a core part of that.” She recalls how Lynparza for ovarian cancer, which has contributed to AstraZeneca’s turnaround, was almost discontinued. “Now it’s a really big drug for us because identified the right patients to treat.”

https://www.theguardian.com/business/2021/nov/24/follow-the-science-astrazeneca-unveils-1bn-rd-centre

Strange that his family circumstances aren’t happening until the end of December.

Anyway, all the best to him. Never wish ill fortune on anyone.

FX, who said she's been offered a board position?

On the work being done, it is undertaken by external CRO's, so Brindleys hands are tied on their delivery timelines. They will agree to the slot in their programme, but they might be delayed by other factors.

The way I see it, if Anne hadn't been employed, its highly likely NFX wouldn't have survived through this year.

"I keep hearing people say how valuable she is and how her knowledge is second to none but I have yet to see any benefit of that for the shareholders of Nuformix."

Without Anne then NXP002 would not be as advanced as it is now, there was simply nobody on the NFX team at this time last year who could have designed the programme that 002 is following.

Yes the sp is at a low, but it is not within Brindleys remit to pump the sp on false news.

She wouldn't be salaried FX, all the NED's are paid on a service basis as is JH as a consultant.
It would be great for Anne to be retained as a consultant, her knowledge on inhaled products is second to none and would be invaluable through the outlicense.

Older, it’s not unusual, NFX’s very own Maddy Kennedy is CFO of Arquer as well as NED of a few others.

Certainly looks that way, they put Alex Eberlin on gardening leave back in January prior to closing the lab, hence he was given a good 500k in options. Although they do have a strike price over 2p and expire next year, so he will be hopeful of them.

The issue is not so much research on the products they have, the lab closure and JH being consultant only signifies they are not researching anything brand new.

Jiving, we've had results on NXP004. That is all they were ever going to give due to commercial sensitivity. When you're sitting on a billion pound drug, you don't say much in public till you know its secure.

Thanks for your invaluable contribution bloodninja.

NXP004 - successful research now plan to approach potential licensees. Potential for further additional data to be added over next 12 months.

NXP002- successful completion of in-vitro, in-Vivo testing, expecting positive results (all about how much positive they are) and now commenced durability testing.

Chab, it was implied in the agm Q&A’s, they’d already pushed it back by a quarter.

Not stressed by this as there is enough positive in the rest of the talk.

FX, the company can’t say that a patent is novel, that is for the patent examiner to determine.

The key take out is that they have said they successfully completed the testing as planned, so now just about durability.